Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
11 2023
Historique:
received: 17 10 2022
revised: 24 08 2023
accepted: 04 09 2023
medline: 13 11 2023
pubmed: 17 9 2023
entrez: 16 9 2023
Statut: ppublish

Résumé

Acceptance and Commitment Therapy for Inpatients (ACT-IN) with psychosis has been found to be efficacious in previous trials, but its effectiveness has not been studied when implemented by frontline clinicians in routine settings. In this pilot randomized controlled effectiveness trial, inpatients with schizophrenia-spectrum disorders were randomized to ACT-IN plus treatment as usual (TAU) (n = 23) or a time/attention matched (TAM) supportive condition plus TAU (n = 23) delivered by routine hospital staff. Both conditions received individual and group therapy during inpatient care and completed follow-up phone sessions during the first month post-discharge. Patients were assessed through 4 months post-discharge (blinded to condition) to determine feasibility, acceptability, and preliminary effectiveness of ACT-IN. ACT-IN was feasible to deliver with fidelity by frontline staff when integrated into an acute care setting. At post-treatment, patients reported significantly greater treatment satisfaction in ACT-IN relative to TAM. Overall, results showed significant but similar improvements for both conditions through 4-month follow-up in psychiatric symptoms, functioning, and mindfulness. Only ACT-IN improved over time in distress. Furthermore, patients receiving TAM had a 3.76 times greater risk of rehospitalization over 4 months compared with ACT-IN. ACT-IN is feasible and acceptable for patients with psychosis, can be implemented by hospital staff when integrated into acute treatment, and may result in decreased rehospitalization compared to alternative therapies. A future full-scale randomized-controlled implementation trial is warranted. gov Identifer: NCT02336581.

Identifiants

pubmed: 37716204
pii: S0920-9964(23)00325-0
doi: 10.1016/j.schres.2023.09.017
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02336581']

Types de publication

Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-79

Subventions

Organisme : NIMH NIH HHS
ID : R34 MH097987
Pays : United States

Informations de copyright

Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Gaudiano has received honoraria from presentations and book royalties related to Acceptance and Commitment Therapy for psychosis. There are no other conflicts of interest to report related to this work.

Auteurs

Brandon A Gaudiano (BA)

Alpert Medical School of Brown University, United States of America; Butler Hospital, United States of America; Providence VA Medical Center, United States of America. Electronic address: Brandon_Gaudiano@brown.edu.

Stacy Ellenberg (S)

SUNY Upstate Medical Center, United States of America.

Jennifer E Johnson (JE)

Michigan State University, United States of America.

Kim T Mueser (KT)

Boston University, United States of America.

Ivan W Miller (IW)

Alpert Medical School of Brown University, United States of America; Butler Hospital, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH